19 June 2013
Keywords: neurex, plans, nda, filing, ziconotide, corp, says
Article | 21 January 1998
Neurex Corp says that it has completed an interim analysis of data frompatients enrolled in a Phase III neuropathic pain ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 April 1998
7 July 1998
18 June 2013
© 2013 thepharmaletter.com